MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWEDEN

被引：0
|
作者：
Holmberg, C. [1 ]
Aultman, R. [2 ]
Siebert, U. [3 ]
Sabate, E. [4 ]
Gyldmark, M. [2 ]
机构：
[1] F Hoffmann La Roche AB, Stockholm, Sweden
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[4] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73307-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [31] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [32] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Nakajima, Go
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 579 - 585
  • [33] Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progressionfree survival in patients with advanced and/or metastatic colorectal cancer
    Wulaningsih, Wahyu
    Wardhana, Ardyan
    Watkins, Johnathan
    Yoshuantari, Naomi
    Repana, Dimitra
    Van Hemelrijck, Mieke
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (02):
  • [34] Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab
    Hidekazu Kuramochi
    Masayuki Ando
    Michio Itabashi
    Go Nakajima
    Kazuyuki Kawakami
    Mie Hamano
    Eiichi Hirai
    Hajime Yokomizo
    Ryuji Okuyama
    Tatsuo Araida
    Kazuhiko Yoshimatsu
    Shingo Kameoka
    Kazuhiko Hayashi
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 579 - 585
  • [35] Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer
    Rocha, Jose Aurillo
    [J]. ANTI-CANCER DRUGS, 2011, 22 : S9 - S13
  • [36] COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE
    Gyldmark, M.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [37] Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802-Analysis of early tumor shrinkage (ETS).
    Yuki, Satoshi
    Nakatsumi, Hiroshi
    Sawada, Kentaro
    Kato, Takashi
    Meguro, Takashi
    Nakamura, Michio
    Iwanaga, Ichiro
    Ehira, Nobuyuki
    Sonoda, Norikazu
    Kudo, Mineo
    Kato, Kanji
    Sogabe, Susumu
    Amano, Toraji
    Ono, Kota
    Sakamoto, Keita
    Miyamoto, Noriyuki
    Kudo, Kohsuke
    Sakamoto, Naoya
    Sakata, Yuh
    Komatsu, Yoshito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Aviri, a large phase II trial of first-line bevacizumab plus infusional 5-FU/leucovorin and irinotecan (FOLFIRI) in metastatic CRC
    Sobrero, Alberto
    Ackland, Stephen
    Carrion, Ramon Perez
    Chiarra, Silvana
    Clarke, Stephen
    Giron, Carlos Garcia
    Langer, Bernd
    Andre, Niko
    Young, Scott
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [39] Cost-effectiveness of Capecitabine plus Irinotecan Versus Leucovorin plus Fluorouracil plus Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China
    Wu, Qiuji
    Zhang, Pengfei
    Wang, Xinyuan
    Zhang, Mengxi
    Liao, Weiting
    Li, Qiu
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (11) : 2148 - +
  • [40] Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110)
    Modest, Dominik Paul
    von Weikersthal, Ludwig Fischer
    Decker, Thomas
    Vehling-Kaiser, Ursula
    Uhlig, Jens
    Schenk, Michael
    Freiberg-Richter, Jens
    Peuser, Bettina
    Denzlinger, Claudio
    Reddemann, Christina Peveling Genannt
    Graeven, Ullrich
    Schuch, Gunter
    Schwaner, Ingo
    Stahler, Arndt
    Jung, Andreas
    Kirchner, Thomas
    Held, Swantje
    Stintzing, Sebastian
    Giessen-Jung, Clemens
    Heinemann, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (01) : 22 - +
12345